Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02549651
Title MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

diffuse large B-cell lymphoma

Therapies

Durvalumab + Tremelimumab

Durvalumab

AZD9150 + Durvalumab

Age Groups: adult | senior
Covered Countries USA | FRA


No variant requirements are available.